Shire plc (SHPG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
200.22+1.13 (+0.57%)
At close: 4:00 PM EDT
People also watch:
JAZZALXNMDVNMNKBMRN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open197.58
Prev Close199.09
Bid197.20 x 100
Ask0.00 x
Day's Range196.92 - 200.74
52wk Range147.60 - 231.32
1y Target EstN/A
Market Cap59.61B
P/E Ratio (ttm)41.61
Beta1.60
Volume1,166,092
Avg Vol (3m)1,194,089
Dividend & Yield0.80 (0.40%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Billionaire James Dinan’s York Capital Initiated Stakes in These Companies
    Insider Monkey2 days ago

    Billionaire James Dinan’s York Capital Initiated Stakes in These Companies

    Though billionaire James Dinan‘s York Capital Management manages regulatory assets worth over $25 billion, its latest 13F filing reveals that less than 16% of it or only $4 billion was invested in US equities at the end of second quarter. The New York-based hedge fund that will be celebrating its silver jubilee this year manages […]

  • Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
    Investor's Business Daily4 days ago

    Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest

    Amgen and Biogen could square off to acquire muscle biologist Cytokinetics, while many players look at Adamas Pharmaceuticals.

  • Reuters4 days ago

    Shire raises eyebrows with stunning debut

    Investors piled into the debut bond from Shire this week, ignoring some clear warning signals that the drugmaker's deal might have offered a little bit less than meets the eye. The US$12.1bn trade amassed a US$28.5bn order book, even as analysts were noting that Shire's debt-to-Ebitda ratio had jumped from less than one time to more than seven times in 12 months. Proceeds will help finance Shire's US$32bn hostile takeover of rival Baxalta, and some of the buyside demand could be put down to investor appetite for all things pharma.